Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

NCT03588091 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

NCT02535221 ·Status: RECRUITING ·Phase: PHASE3

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

NCT02980965 ·Status: COMPLETED ·Phase: PHASE3

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

NCT04158856 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

NCT05633914 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

NCT07340398 ·Status: RECRUITING ·Phase: PHASE2

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

NCT06722599 ·Status: RECRUITING

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

NCT05189067 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

NCT04973319 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

NCT05673850 ·Status: COMPLETED

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

NCT05728268 ·Status: RECRUITING ·Phase: PHASE2

Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer

NCT00209092 ·Status: COMPLETED ·Phase: PHASE2

Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy

NCT06596018 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs

NCT02510781 ·Status: UNKNOWN ·Phase: PHASE2

Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

NCT05891561 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

NCT04290793 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer

NCT01907529 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

NCT06035679 ·Status: RECRUITING ·Phase: NA

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

NCT06791161 ·Status: ENROLLING_BY_INVITATION

Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm

NCT00776724 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

NCT06832904 ·Status: RECRUITING ·Phase: PHASE2

Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer

NCT03147963 ·Status: UNKNOWN ·Phase: PHASE2

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

NCT00386087 ·Status: COMPLETED ·Phase: PHASE2

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

NCT04337658 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3